Silji Abraham, SVP, Chief Technology Officer of West Pharmaceutical Services Inc (WST, Financial), has sold 7,012 shares of the company on February 23, 2024, according to a recent SEC Filing. The transaction was executed at a stock price of $365, resulting in a total value of $2,559,380.
West Pharmaceutical Services Inc is a global leader in the design and production of containment and delivery systems for injectable drugs and healthcare products. The company's portfolio includes vial containment solutions, prefillable syringe systems, self-injection platforms, and other products designed to ensure the safe, reliable administration of pharmaceuticals.
Over the past year, the insider has sold a total of 24,692 shares of West Pharmaceutical Services Inc and has not made any purchases of the stock.
The insider transaction history for West Pharmaceutical Services Inc shows a pattern of 18 insider sells and no insider buys over the past year.
On the day of the insider's recent sale, shares of West Pharmaceutical Services Inc were trading at $365, giving the company a market cap of $26.461 billion. The price-earnings ratio of the stock stands at 45.81, which is above both the industry median of 27.955 and the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 0.96, with a GF Value of $379.89, indicating that West Pharmaceutical Services Inc is fairly valued based on its GF Value.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
